Zobrazeno 1 - 10
of 283
pro vyhledávání: '"Lung I"'
Autor:
Huang, Lung-I, Yang, Yanfei, Elmquist, Randolph E., Lo, Shun-Tsung, Liu, Fan-Hung, Liang, Chi-Te
We report on magneto-transport measurements on low-density, large-area monolayer epitaxial graphene devices grown on SiC. We show that the zero-energy Landau level (LL) in monolayer graphene, which is predicted to be magnetic field ($B$)-independent,
Externí odkaz:
http://arxiv.org/abs/1602.08198
Autor:
Yang, Yanfei, Huang, Lung-I, Fukuyama, Yasuhiro, Liu, Fan-Hung, Real, Mariano A., Barbara, Paola, Liang, Chi-Te, Newell, David B., Elmquist, Randolph E.
Monolayer epitaxial graphene (EG) grown on hexagonal Si-terminated SiC substrates is intrinsically electron-doped (carrier density is about 10^13 cm^(-2)). We demonstrate a clean device fabrication process using a precious-metal protective layer, and
Externí odkaz:
http://arxiv.org/abs/1404.1048
Autor:
LUNG-I CHENG1, DALE, JENNA2
Publikováno v:
Pharmaceutical Executive. Jul/Aug2024, Vol. 44 Issue 7/8, p24-25. 2p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tanja Podkonjak, Holly Cranmer, Julia Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng
Publikováno v:
Journal of Comparative Effectiveness Research. 11:193-202
Aim: To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials & methods: A partitioned-survival model was developed from the Nat
Autor:
Aguilar, Erwin A. *, Barry, Sean D., Cefalu, Charles A., Abdo, Abir, Hudson, William P., Campbell, James S., Reske, Thomas M., Bonafede, Machaon, Wilson, Kathleen, Stolshek, Bradley S., Paoli, Carly J., Tran, Nguyet, Cheng, Lung-I
Publikováno v:
In The American Journal of the Medical Sciences November 2015 350(5):357-363
Publikováno v:
In Journal of the American Medical Directors Association 1 April 2015 16(4):341-348
Autor:
Peter P. Toth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I. Cheng, Ian Bridges, Gavin M. Worth, Ricardo Dent, Carol A. Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S. G. Stroes
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 10 (2017)
BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reducti
Externí odkaz:
https://doaj.org/article/7f9fd7632f2a455c94947fb72b3ea045